SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Panacos Attracts $18.3M Round To Fund HIV Drug Development (BioWorld Today)
News | 04. 16. 2008
Panacos Pharmaceuticals
Panacos Pharmaceuticals Inc. raised $18.3 million in its Series C round of financing.
